3,4-dichlorocinnamoyl chloride | 39156-98-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3,4-dichlorocinnamoyl chloride
• 英文别名: 3,4-Dichlor-cinnamoylchlorid；3-(3,4-dichlorophenyl)prop-2-enoyl chloride
• CAS: 39156-98-4
• 化学式: C₉H₅Cl₃O
• mdl: MFCD09752198
• 分子量: 235.497
• InChiKey: SQOOOIAYRCYPSW-UHFFFAOYSA-N

物化性质

• 沸点：
  340.2±32.0 °C(Predicted)
• 密度：
  1.446±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  3,4-dichlorocinnamoyl chloride 在 四溴化碳 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 3.33h， 生成 (E)-N-(5-bromopentyl)-3-(3,4-dichlorophenyl)acrylamide
  参考文献：
  名称：

  CCR2:  Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach

  摘要：

  We describe here a classical molecular modeling exercise that was carried out to provide a basis for the design of novel antagonist ligands of the CCR2 receptor. Using a theoretical model of the CCR2 receptor, docking studies were carried out to define plausible binding modes for the various known antagonist ligands, including our own series of indole piperidine compounds. On the basis of these results, a number of site-directed mutations (SDM) were designed that were intended to verify the proposed docking models. From these it was clear that further refinements would be necessary in the model. This was aided by the publication of a crystal structure of bovine enabled us to define ligand-docking hypotheses that were in complete agreement with the results of the SDM experiments.

  DOI：

  10.1021/jm030862l
• 作为产物：
  描述：

  3,4-二氯肉桂酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 3,4-dichlorocinnamoyl chloride
  参考文献：
  名称：

  Synthesis and Anti-influenza Activities of Novel Baicalein Analogs

  摘要：

  一系列新型黄酮衍生物是基于对传统中药黄芩（Scutellaria baicalensis GEORGI）活性成分的修饰合成的，并进行了抗流感活性筛选。合成的大黄素（黄酮）类似物，特别是B环上带有溴原子取代的类似物，对H1N1达菲耐药（H1N1 TR）病毒的活性远超奥司他韦或利巴韦林，并且通常具有更优越的选择性。最有希望的化合物是5b、5c、6b和6c，它们的50%有效浓度（EC50）都在4.0–4.5 µM左右，选择指数（SI=50%细胞毒性浓度（CC50）/EC50）>70。对于季节性H3N2流感病毒感染，5a和5b的SI均大于17.3，优于利巴韦林。这些具有非天然溴取代B环和A环上适当羟基位置的黄酮类化合物可能在决定抗H1N1达菲耐药流感病毒的活性和选择性方面起关键作用。

  DOI：

  10.1248/cpb.c13-00897

文献信息

• Synthesis and Antiviral Activity of New Derivatives of Rupestonic Acid
  作者：L. Chen、M. Obul、Kh. Bozorov、J. Zhao

  DOI：10.1007/s10600-021-03497-6

  日期：2021.9

  A series of 20 new derivatives of rupestonic acid were synthesized via Davis oxidation. Their antiviral activity against influenza A virus (H3N2) was established. Several of the synthesized compounds were shown to exhibit antiviral activity against influenza A virus. Compound 4d was shown to have the highest potential activity (R = α-methylcinnamyl acyl with IC50 14.37 μg/mL and TC50 80.13 μg/mL) against influenza A virus.

  通过Davis氧化法，合成了一系列20种新的岩藻酸衍生物，并确定了它们对流感A病毒（H3N2）的抗病毒活性。合成的一些化合物表现出了对流感A病毒的抗病毒活性，化合物4d显示出最高的潜在活性（R = α-甲基肉桂酰基，IC50为14.37 μg/mL，TC50为80.13 μg/mL）。
• Synthesis and Anticancer Activity of Podophyllotoxin Derivatives
  作者：K. Lin、X. Zhang、X. Dai、L. Ma、K. Bozorov、H. Guo、G. Huang、J. Cao

  DOI：10.1007/s10600-021-03539-z

  日期：2021.11

  Two series of podophyllotoxin derivatives were synthesized by addition of a 4β-sulfanilamide to or substitution of a 4β-amide into podophyllotoxin. Their cytotoxicities were evaluated against four human cancer cell lines (A549, HeLa, MCF-7, and PC-3). Investigations of the structure–activity relationship were generalized. Derivative 9f (2-thienoylaminoepipodophyllotoxin) exhibited the highest activity against the cancer cells, inhibiting growth of MCF-7 cells with IC50 0.67 ± 0.37 μM. A change in the morphology of MCF-7 cells treated with 9f also confirmed its activity as a cytotoxic derivative against cancer cells.

  通过向鬼臼毒素的4β位引入磺胺或用酰胺替换4β位的羟基，合成了两系列鬼臼毒素衍生物。它们对四种人癌细胞系（A549、HeLa、MCF-7和PC-3）的细胞毒性进行了评估，并概括了这些衍生物的构效关系。其中，衍生物9f（2-噻吩酰氨基表鬼臼毒素）显示出最高的抗癌活性，对MCF-7细胞的抑制生长IC50值为0.67 ± 0.37 μM。9f处理后的MCF-7细胞形态变化也证实了其作为抗癌细胞毒性衍生物的活性。
• Synthesis and Anti-influenza Activities of Novel Baicalein Analogs
  作者：Shu-Ting Chung、Pei-Yu Chien、Wen-Hsin Huang、Chen-Wen Yao、An-Rong Lee

  DOI：10.1248/cpb.c13-00897

  日期：——

  A series of novel flavones derivatives were synthesized based on modification of the active ingredients of a traditional Chinese medicine Scutellaria baicalensis GEORGI and screened for anti-influenza activity. The synthetic baicalein (flavone) analogs, especially with the B-rings substituted with bromine atoms, were much more potent than oseltamivir or ribavirin against H1N1 Tamiflu-resistant (H1N1 TR) virus and usually with more favorable selectivity. The most promising were 5b, 5c, 6b and 6c, all displaying an 50% effective concentration (EC50) at around 4.0–4.5 µM, and a selective index (SI=50% cytotoxic concentration (CC50)/EC50)>70. For seasonal H3N2-infected influenza virus, both 5a and 5b with SI >17.3 indicated superior to ribavirin. The flavonoids having both not-naturally-occurring bromo-substituted B-rings and appropriate hydroxyls positioning on the A-rings might be critical in determining the activity and selectivity against H1N1-Tamiflu-resistant infected influenza viruses.

  一系列新型黄酮衍生物是基于对传统中药黄芩（Scutellaria baicalensis GEORGI）活性成分的修饰合成的，并进行了抗流感活性筛选。合成的大黄素（黄酮）类似物，特别是B环上带有溴原子取代的类似物，对H1N1达菲耐药（H1N1 TR）病毒的活性远超奥司他韦或利巴韦林，并且通常具有更优越的选择性。最有希望的化合物是5b、5c、6b和6c，它们的50%有效浓度（EC50）都在4.0–4.5 µM左右，选择指数（SI=50%细胞毒性浓度（CC50）/EC50）>70。对于季节性H3N2流感病毒感染，5a和5b的SI均大于17.3，优于利巴韦林。这些具有非天然溴取代B环和A环上适当羟基位置的黄酮类化合物可能在决定抗H1N1达菲耐药流感病毒的活性和选择性方面起关键作用。
• [EN] RODENTICIDAL NORBORMIDE ANALOGUES<br/>[FR] ANALOGUES DE NORBORMIDE RODENTICIDE
  申请人：LANDCARE RES NEW ZEALAND LTD

  公开号：WO2013133726A1

  公开（公告）日：2013-09-12

  The present invention relates to norbormide analogues having rodenticidal activity; rodenticidal compositions comprising the analogues; uses of the analogues as rodenticides; uses of the analogues in the manufacture of rodenticidal compositions; and methods for controlling rodents using the compositions.

  本发明涉及具有杀鼠活性的诺波酰胺类似物；包括这些类似物的杀鼠组合物；将这些类似物用作杀鼠剂的用途；将这些类似物用于制造杀鼠组合物的用途；以及使用这些组合物控制啮齿动物的方法。
• Benzo[b]pyrano[3,2-h]acridin-7-one cinnamate compounds
  申请人：Koch Michel

  公开号：US20060135545A1

  公开（公告）日：2006-06-22

  A compound selected from those of formula (I): wherein: X and Y represent a group selected from hydrogen, halogen, alkoxy, nitro, cyano, alkyl, alkenyl, polyhaloalkyl and —NR a R b wherein R a and R b are as defined in the description, Z represents oxygen or NR c wherein R c is as defined in the description, Ar represents aryl or heteroaryl, R 1 represents hydrogen or alkyl, R 2 represents a group selected from hydrogen, alkyl, —OR a and —NR a R b wherein R a and R b are as defined in the description, R 3 and R 4 represent hydrogen or alkyl, R 5 represents hydrogen, OR c , NR c R d , W 1 —C(W 2 )—U—V, W 1 —C(W 2 )—W 3 -T 1 or Z-CO—CH═CHAr wherein R c , R d , W 1 , W 2 , W 3 , U, V, T, Z and Ar are as defined in the description, its isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.

  从式（I）中选择的一种化合物： 其中： X和Y代表从氢、卤素、烷氧基、硝基、氰基、烷基、烯基、多卤代烷基和-NR a R b 中选择的基团， 其中R a 和R b 如描述中所定义， Z代表氧或NR c 其中R c 如描述中所定义，Ar代表芳基或杂环芳基， R 1 代表氢或烷基， R 2 代表从氢、烷基、-OR a 和-NR a R b 中选择的基团，其中R a 和R b 如描述中所定义， R 3 和R 4 代表氢或烷基， R 5 代表氢、OR c 、NR c R d 、W 1 -C(W 2 )-U-V、W 1 -C(W 2 )-W 3 -T 1 或Z-CO-CH═CHAr其中R c 、R d 、W 1 、W 2 、W 3 、U、V、T、Z和Ar如描述中所定义，其异构体，以及其与药学上可接受的酸或碱形成的加合盐，以及含有这种化合物的用于治疗癌症的药物。